Jiuzhitang Co., Ltd.: history, ownership, mission, how it works & makes money

From a Qing Dynasty pharmacy established in 1650 to a Shenzhen-listed enterprise (stock code 000989) that melds centuries-old TCM with modern biotech, Jiuzhitang Co., Ltd. has charted a remarkable trajectory-formally founded in 1999, listed on June 28, 2000, and in 2012 investing nearly 700 million yuan to build a high-tech industrial park; today it operates a vertically integrated model with over 30 branches, more than 500 chain stores, some 1,500 distributors and close to 30,000 retail outlets, a product portfolio exceeding 200 SKUs, and R&D momentum evidenced by a subsidiary obtaining clinical trial approval in 2025, while financials underline momentum (total revenue of 2.1 billion yuan in 2022, up 14% year-over-year, distribution revenue around 1.78 billion yuan in 2021) and investor confidence (market capitalization about 8.58 billion yuan as of November 4, 2025) as the company leverages a 53.3 billion yuan-valued brand to pursue prevention, treatment and rehabilitation across China's booming health market.

Jiuzhitang Co., Ltd. (000989.SZ): Intro

• Founding lineage: Laojiuzhitang Pharmacy Store (est. 1650).
• Modern corporate establishment: 1999 (company reorganized/established in its current corporate form).
• Public listing: Shenzhen Stock Exchange, 28 June 2000 (stock code 000989).
• Cultural recognition: 'Chinese Time-honored Brand' (Ministry of Commerce, 2006).
• Intangible cultural heritage listing: TCM culture of Jiuzhitang added to national protection catalogue (2008).
• Major capital investment: ~RMB 700 million invested to build Jiuzhitang High-tech Industrial Park (2012).

History & Key Milestones

Ownership & Corporate Structure

• Listed company structure (A-share, Shenzhen Stock Exchange, code 000989) with typical shareholder composition of institutional investors, retail investors and controlling shareholders from the corporate group or founding entities.
• Operational subsidiaries cover TCM decoction pieces, prepared Chinese medicines, health products, and distribution networks including pharmacies and hospital supply channels.

Mission, Brand & Cultural Positioning

• Mission: Preserve and modernize traditional Chinese medicine through standardized production, quality control and R&D while promoting TCM cultural heritage.
• Brand positioning: Heritage TCM leader leveraging authenticity (centuries-old formulations), certified production and cultural recognition to differentiate from mass-market competitors.

How Jiuzhitang Works - Business Model & Revenue Streams

• Manufacturing and sales of TCM products: finished patented Chinese medicines, decoction pieces, granules and proprietary formulas produced in GMP/modern facilities (including the High-tech Industrial Park).
• Pharmacy and retail distribution: the company's branded stores, third-party pharmacy channels and e-commerce platforms.
• Hospital and institutional sales: supplying hospitals, clinics and TCM practitioners with prepared medicines and decoction materials.
• OEM/contract manufacturing and co-branding: production services for other pharmaceutical brands or partners.
• R&D, cultural IP and licensing: monetizing heritage formulations, TCM cultural IP, and participating in collaborative research projects.

Operational Capabilities & Investments

• Jiuzhitang High-tech Industrial Park (2012): nearly RMB 700 million investment to introduce modern extraction, granulation, sterile preparation, packaging lines and quality control labs aligned with national GMP/production standards.
• Quality assurance: modern testing laboratories for raw materials and finished products, standardization of classical prescriptions to modern dosage forms (granules, capsules, injections where applicable).

Financial & Market Considerations (structure, not forward guidance)

Jiuzhitang Co., Ltd. (000989.SZ): History

• Founded origin: traditional TCM enterprise with multi-decade history in herb processing and decoction pieces.
• Listed: Shenzhen Stock Exchange under code 000989 (public listing accelerated access to capital for scale-up).
• Strategic shifts: investment in GMP production, diversified product portfolio (TCM extracts, patented medicines, health supplements), and expanded retail/distribution network.

• Public listing: Jiuzhitang is a publicly traded company (000989.SZ) with a market capitalization of approximately 8.58 billion yuan as of November 4, 2025.
• Shareholder mix: diversified base including institutional investors, individual retail shareholders, and employee holdings-supporting liquidity and alignment with growth strategies.
• Regulatory oversight: subject to China Securities Regulatory Commission rules, with routine disclosure of ownership, related-party transactions, and governance in annual and interim reports.
• Governance: board of directors and executive management oversee strategic decision-making, risk management, and compliance; committees address audit, nomination, and remuneration.

• Core activities: R&D of patent TCM formulations, large-scale manufacturing of herbal extracts and finished dosage forms, and multi-channel sales (wholesale to hospitals, pharmacies, and direct retail/online).
• Monetization: product sales (prescription and OTC TCM), contract manufacturing, licensing of proprietary formulations, and retail network margins.
• Vertical integration: in-house herb sourcing and processing lowers input costs and improves traceability, supporting margin stability.

Jiuzhitang Co., Ltd. (000989.SZ): Ownership Structure

• Stock code: 000989.SZ (A-share listed on Shenzhen Stock Exchange).
• Heritage recognition: TCM culture entry to national intangible cultural heritage catalogue, 2008.
• Brand value: 53.3 billion yuan (end of 2020).

• Mission and values:
  • Provide precise, effective whole-life-cycle health management covering prevention, treatment and rehabilitation.
  • Integrate traditional Chinese medicine with modern biomedical technologies to offer comprehensive health solutions.
  • Emphasize innovation through inheritance-develop via innovation while preserving TCM roots.
  • Prioritize product quality and integrity-high safety and efficacy standards.
  • Preserve cultural heritage and promote TCM culture nationally and internationally.

• How Jiuzhitang makes money:
  • Product sales: traditional medicine formulations, patented TCM products and health supplements sold through retail and institutional channels.
  • Healthcare services: clinics and rehabilitation services delivering integrated TCM and biomedical treatments.
  • R&D and technology licensing: development of modernized TCM formulations and biomedicine integrations.
  • Brand premium and cultural licensing: leveraging strong brand recognition (53.3 billion yuan in 2020) and cultural IP for premium pricing and collaborations.

Jiuzhitang Co., Ltd. (000989.SZ): Mission and Values

• Research & Development: in-house R&D and specialized subsidiaries advancing new drug development and regenerative medicine initiatives.
• Manufacturing: centralized, GMP-compliant production including an intelligent Chinese herb factory for automated processing and quality control.
• Sales & Distribution: multi-channel sales comprising proprietary chain stores, distributors, wholesale partners and third-party retail outlets.
• Healthcare Services: health management and clinical service offerings linked to product lines to support patient outcomes and repeat prescriptions.

• Organizational footprint: over 30 branches and subsidiaries.
• Retail presence: more than 500 Jiuzhitang chain stores.
• Distribution: in excess of 1,500 distributors and nearly 30,000 retail outlets across China.

• Recognized as a national-level innovative pilot enterprise.
• Designated as a key construction unit of TCM engineering under the National Administration of TCM.

• Subsidiary Jiuzhitang Meike (Beijing) Stem Cell Technology Co., Ltd. secured clinical trial approval for a new drug in 2025, representing a strategic move into regenerative-biotech-enabled therapeutics.
• Ongoing investments in formulation modernization, quality traceability (raw-material to finished product) and digital health tools for patient management.

• Proprietary product sales: branded TCM formulations sold through company chain stores and retail partners.
• Wholesale & distribution: bulk sales to distributors and healthcare institutions.
• OEM/contract manufacturing: production services for third-party TCM brands and partners.
• Healthcare services: paid health management programs, clinic-driven prescriptions and ancillary services.
• Biotech/R&D commercialization: licensing, clinical-stage asset development (e.g., stem-cell related therapies) and potential future drug approvals/royalties.

• Vertical integration reduces margin leakage between manufacturing and retail, improving gross margin capture.
• Large distributor and retail footprint enables scale for promotional campaigns, new product rollouts and cross-selling of health services.
• R&D pipeline and biotech subsidiaries create optionality for higher-margin therapeutics and licensing income as assets progress through clinical development.

Jiuzhitang Co., Ltd. (000989.SZ): How It Works

• Primary revenue streams: prescription TCM, OTC supplements, proprietary formulations, and licensed products.
• Distribution channels: hospitals and clinics, retail pharmacies, third-party distributors, and e-commerce platforms (cross-border and domestic).
• Value drivers: established brand recognition in TCM, extensive distributor relationships, scale manufacturing, and continuous product development.

• Sourcing and manufacturing: vertical integration of raw TCM herbs processing, GMP-compliant production lines, and batch quality control.
• R&D and product pipeline: development of classical formulae and modernized dosage forms to extend OTC and prescription offerings.
• Channel management: direct sales to institutional buyers (hospitals), partnerships with nationwide distributors, and growth via online retail.
• Regulatory and disclosure practices: periodic financial reporting and annual filings to inform stakeholders of performance and compliance.

• Manufacturing → Bulk sales to distributors and hospitals: large-volume contracts with payment terms drive working capital cycle.
• Retail/OEM sales → Pharmacies and e-commerce: higher margin per unit for branded OTC products sold via retail and online channels.
• Institutional contracts → Prescription supply agreements: stable recurring revenue from hospital and clinic procurement.
• Licensing & co-development: occasional licensing and collaboration revenues from partners modernizing TCM formulations.

Jiuzhitang Co., Ltd. (000989.SZ): How It Makes Money

• Core product sales: patented and branded Chinese patent medicines, decoction pieces and healthcare products sold through a wide retail and distributor network.
• Institutional & hospital sales: bulk supply to hospitals, clinics and health institutions leveraging state-enterprise relationships and TCM project status.
• Pharmaceutical R&D and pipelines: subsidiaries pursuing new-drug approval and clinical-stage assets (clinical trial approvals obtained in 2025), creating higher-margin future product streams.
• Licensing & brand monetization: licensing of proprietary formulas, co-development with biotech partners, and premiumization of legacy brands.
• Health services and chain operations: branded pharmacies, TCM clinics and wellness services that capture downstream retail margins.

• Strong brand equity (53.3 billion yuan in 2020) and entrenched distribution give Jiuzhitang a durable competitive moat in TCM consumer markets.
• State-enterprise status and designation as a national pilot and key TCM engineering unit strengthen government ties and preferential access to public-sector channels and policy support.
• R&D trajectory - clinical approvals in 2025 - signals a strategic pivot toward higher-value pharmaceutical assets and biologics that can materially expand margins and diversify revenue.
• Large-scale retail penetration (≈30,000 outlets) plus digital and institutional channels positions the company for scale-up as China's healthcare and wellness demand grows.
• Integration of TCM with modern biomedical technologies aims to capture premium, regulated drug markets and health-tech collaborations, enhancing long-term valuation upside.